Secretory co-factors in next-generation cellular therapies for cancer

Since chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies were approved by the U.S. Food and Drug Administration, numerous “next-generation” CAR T cells have been developed to improve their safety, efficacy, and applicability. Although some of these novel therapeutic strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuma, Atsushi, Ishida, Yoshihito, Kawara, Taketo, Hisada, Shoji, Araki, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433659/
https://www.ncbi.nlm.nih.gov/pubmed/36059449
http://dx.doi.org/10.3389/fimmu.2022.907022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433659/
https://www.ncbi.nlm.nih.gov/pubmed/36059449
http://dx.doi.org/10.3389/fimmu.2022.907022

Ejemplares similares